淋巴瘤患者治疗前血清细胞因子升高与外周血免疫抑制细胞标志物的关联
研究纳入390例未经治疗的弥漫大B细胞、滤泡、套细胞、T细胞及霍奇金淋巴瘤患者,检测12种血清细胞因子与淋巴细胞/单核细胞比值(ALC/AMC)的关系。全队列中ALC/AMC比值降低与IL-2R、IL-12、IP-10、MIG浓度升高轻度相关;IL-2R升高独立关联ALC受抑、AMC升高及ALC/AMC比值受抑,且IL-2R升高与ALC/AMC比值受抑均独立关联总生存期较差。
要点
- 全队列中ALC/AMC比值降低与IL-2R(r=-0.36)、IL-12(r=-0.17)、IP-10(r=-0.23)、MIG(r=-0.32)升高轻度相关,p<0.001。
- IL-2R升高独立关联ALC受抑(OR 2.69)、AMC升高(OR 2.05)及ALC/AMC比值受抑(OR 3.51),p均<0.001。
- IL-2R升高(HR 2.27)与ALC/AMC比值受抑(HR 1.53)均独立关联总生存期较差。
核心结论
- 数据支持治疗前血清细胞因子升高具有免疫抑制作用这一观点,并为靶向肿瘤微环境以获取治疗获益提供进一步依据。
研究设计与样本
- 研究检测了390例未经治疗的弥漫大B细胞、滤泡、套细胞、T细胞及霍奇金淋巴瘤患者的12种血清细胞因子与ALC/AMC比值。
主要发现
- 不同治疗前血清细胞因子浓度与ALC、AMC及ALC/AMC比值的相关性因淋巴瘤类型而异。
- 全队列(n=390)中ALC/AMC比值降低与IL-2R(r=-0.36)、IL-12(r=-0.17)、IP-10(r=-0.23)、MIG(r=-0.32)浓度升高轻度相关,p<0.001。
- IL-2R升高独立关联ALC受抑(OR 2.69,95%CI 1.77-4.07,p<0.001)、AMC升高(OR 2.05,95%CI 1.34-3.14,p<0.001)及ALC/AMC比值受抑(OR 3.51,95%CI 2.31-5.34,p<0.001)。
- IL-2R升高(HR 2.27,95%CI 1.48-3.49,p<0.001)与ALC/AMC比值受抑(HR 1.53,95%CI 1.03-2.28,p=0.037)均独立关联总生存期较差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Higher ratios of the pre-treatment peripheral blood absolute lymphocyte (ALC) to absolute monocyte counts (AMC) are associated with improved outcomes in lymphoma. Conversely, elevated pre-treatment serum cytokines are associated with inferior outcomes. The relationship between pre-treatment serum cytokines and ALC/AMC ratios remains unknown. We studied twelve serum cytokines and the ALC/AMC ratios in 390 patients with untreated diffuse large B-cell, follicular, mantle cell, T-cell, and Hodgkin lymphoma. Different pre-treatment serum cytokine concentrations correlated with ALC, AMC, and ALC/AMC ratios depending on the lymphoma type. In the entire cohort (n = 390) lower ALC/AMC ratios modestly correlated with higher IL-2R (r = -0.36), IL-12 (r = -0.17), IP-10 (r = -0.23), and MIG (r = -0.32) concentrations (p < 0.001). Elevated IL-2R was independently associated with suppressed ALC (OR 2.69, 95% CI 1.77-4.07, p < 0.001), elevated AMC (OR 2.05, 95% CI 1.34-3.14, p < 0.001), and suppressed ALC/AMC ratios (OR 3.51, 95% CI 2.31-5.34, p < 0.001). Both elevated IL-2R (HR 2.27, 95% CI 1.48-3.49, p < 0.001) and suppressed ALC/AMC ratios (HR 1.53, 95% CI 1.03-2.28, p = 0.037) were independently associated with inferior overall survival. These data support the notion that elevated serum cytokines are immunosuppressive and provide further rationale to target the tumor microenvironment for therapeutic benefit.
引用
- Binder M, O'Byrne MM, Maurer MJ, et al. Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. Am J Hematol. 2017. PMID: 28383112. doi:10.1002/ajh.24758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。